Rating Change
Morgan Stanley reiterated its Equal-Weight rating on Moderna, Inc. (NASDAQ:MRNA) on November 17, 2026.
Morgan Stanley reiterated its Equal-Weight rating on Moderna, Inc. (NASDAQ:MRNA) on November 17, 2026.

At publication ·
Moderna, Inc. (NASDAQ:MRNA) · reiterate
At a glance
Morgan Stanley reiterated its Equal-Weight rating on Moderna, Inc. (NASDAQ:MRNA) on November 17, 2026.
Moderna, Inc. operates in the Healthcare sector. The stock currently trades at $206.80 with a market capitalization of $11.6B. The stock has gained 409.6% over the past 52 weeks.
Analyst coverage from Morgan Stanley provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Moderna, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 2 Buy, 6 Hold, 2 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 17, 2026 | JP Morgan | Underweight | N/A |
| Nov 17, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Nov 09, 2026 | Piper Sandler | Overweight | N/A |
| Nov 09, 2026 | Goldman Sachs | Neutral | N/A |
| Oct 27, 2026 | William Blair | Market Perform | N/A |
Related Tools: Analyst Ratings Dashboard | View MRNA Stock Page
A rating of Equal-Weight from Morgan Stanley reflects the analyst's outlook on Moderna, Inc. (NASDAQ:MRNA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the MRNA forecast page.
Current market data
NASDAQ · MRNA
$196.79
Down: -$10.01 · -4.84%
Live quote updated
Keep reading